TAAT Provides Update on Status of MCTO
TAAT Provides Update on Status of MCTO
LAS VEGAS and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- TAAT GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the "Company" or "TAAT") is providing this update on the status of a management cease trade order granted on March 1, 2023 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 – Management Cease Trade Order ("NP 12-203"). On March 1, 2023, the Company announced that, for reasons disclosed in the news release, there would be a delay in the filing of its financial statements and accompanying management's discussion and analysis for the fiscal year ended October 31, 2022 (the "Annual Filings") beyond the period prescribed under applicable Canadian securities laws (the "Default Announcement").
拉斯維加斯和溫哥華，不列顛哥倫比亞省，2023 年 3 月 15 日（環球美通社）--年 全球替代公司（CSE：塔 AT）（OTCQX：托巴夫）（法蘭克福：2TP）（「公司」或「TAAT」「) 正在就不列顛哥倫比亞省證券委員會根據國家政策 12-203 — 管理停止交易令（「NP 12-203」）發出的管理停止交易訂單（「MCTO」）的狀態提供此更新。2023 年 3 月 1 日，本公司宣布，基於新聞稿中披露的原因，在適用的加拿大證券法規定的期限（「預設公告」）之後，其財務報表及隨附管理層就截至 2022 年 10 月 31 日的會計年度（「年度申報」）進行討論和分析將有所延遲。
The Company reports that the audit is progressing and a further update on the timing of the filing of the Annual Filings is anticipated to occur on or about March 24, 2023. Further updates on timing will be provided by the Company as necessary.
公司報告，審計正在進行中，預計將於 2023 年 3 月 24 日或左右發生有關年度申報的提交時間的進一步更新。本公司將根據需要提供有關時間的進一步更新。
During the MCTO, the general investing public will continue to be able to trade in the Company's listed common shares. However, the Company's Chief Executive Officer and Chief Financial Officer will not be able to trade in the Company's common shares.
在 MCTO 期間，一般投資大眾將繼續能夠買賣該公司的上市普通股。然而，本公司的首席執行官兼財務總監將無法買賣本公司的普通股。
Other than as disclosed in this news release, there are no material changes to the information contained in the Default Announcement. The Company confirms that it intends to satisfy the provisions of NP 12- 203 and will continue to issue bi-weekly default status reports for so long as it remains in default of the Annual Filings requirement.
除本新聞稿所披露之外，預設公告中所包含的資訊並無重大變更。該公司確認打算符合 NP 12-203 的規定，並將繼續發出每兩週的違約狀態報告，只要該報告仍不符合年度申報規定。
On behalf of the Board of Directors of the Company,
代表本公司董事會，
TAAT GLOBAL ALTERNATIVES INC.
塔特 全球替代公司
"Michael Saxon"
迈克尔·撒克逊
Michael Saxon, CEO and Director
邁克爾·撒克遜，首席執行官兼董
For further information, please contact:
欲了解更多信息，請聯繫：
TAAT Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatglobal.com
塔特 投資者關係
1-893-天，美國 (1-833-822-8872)
investor@taatglobal.com
THE CANADIAN SECURITIES EXCHANGE ("CSE") HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE'S REGULATION SERVICES PROVIDER.
加拿大證券交易所 (「CSE」) 沒有審閱，也不對此新聞稿的準確性或充分性負責，也沒有或沒有該公司的監管服務供應商。
About TAAT Global Alternatives Inc.
關於國泰 全球替代品公司
TAAT is a vertically integrated consumer product and distribution company, generating more than CAD $90 million in overall gross revenue annually. TAAT is strategically expanding its product categories including tobacco and reduced-risk alternatives, hemp, kratom, and other emerging CPG segments. TAAT has facilities to include a processing plant in Nevada as well as a distribution centre in Canton, Ohio, leveraging existing retail shelf space and pipelines into national wholesale channels.
塔特 是一家垂直整合的消費品和分銷公司，每年產生超過 9000 萬加元的總收入。塔特 正在戰略上擴大其產品類別，包括煙草和降低風險替代品, 大麻, kratom, 和其他新興的 CPG 細分市場.塔特 擁有設施包括內華達州的加工廠，以及位於俄亥俄州坎頓的配送中心，利用現有的零售貨架空間和管道進入國家批發渠道。
For more information, please visit .
欲了解更多信息，請訪問 。
Forward-Looking Statements
前瞻性陳述
Certain information contained herein may constitute "forward-looking information" or "forward-looking statements" under Canadian securities legislation. Generally, forward-looking information can be identified by words such as "pro forma", "plans", "expects", "may", "should", "could", "will", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or variations including negative variations thereof of such words and phrases that refer to certain actions, events or results that may, occur or be taken or achieved. Such forward-looking statements, including but not limited to statements relating to the expected development and operations of the Company, statements concerning the timing, review, completion and filing of the Annual Filings as well as the duration of the MCTO, involve risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Corporation will not update any forward-looking statements or forward-looking information included herein, except as required by applicable securities laws.
本文中包含的某些信息可能構成加拿大證券法例下的「前瞻性信息」或「前瞻性聲明」。通常，前瞻性信息可以通過諸如「備考」，「計劃」，「期望」，「可能」，「應該」，「可能」，「意志」，「預算」，「計劃」，「預測」，「意圖」，「預測」，「預測」，「相信」或變化，包括此類動作的負面變化或可能引用某些行動的詞組的負面變化, 發生或被採取或實現.該等前瞻性陳述，包括但不限於與本公司預期發展及營運有關的陳述、有關年度檔案的時間、覆核、完成及提交，以及《條例》的期限，涉及風險、不明朗因素及其他可能導致實際結果與該等前瞻性陳述或前瞻性資料所表示或暗示的因素有重大不同。不能保證這些陳述將被證明是準確的，因為實際結果和未來事件可能與此類聲明中預期的事件有很大不同。因此，讀者不應過度依賴前瞻性陳述和前瞻性信息。本公司不會更新本文所包含的任何前瞻性陳述或前瞻性資料，但適用證券法例的要求除外。
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company's products will vary from person to person. No claims or guarantees can be made as to the effects of the Company's products on an individual's health and well-being. The Company's products are not intended to diagnose, treat, cure, or prevent any disease.
本新聞稿中的聲明尚未經加拿大衛生部或美國食品和藥物管理局的評估。由於每個人都不同，服用本公司產品的好處（如果有的話）將因人而異。本公司的產品對個人健康和福祉的影響不得提出任何索賠或擔保。本公司的產品並非用於診斷、治療、治愈或預防任何疾病。
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
本新聞稿可能包含第三方實體的商標名稱（或其各自具有商標名稱的產品），通常是參照本公司與本發行版中所述第三方實體的關係，以及/或（ii）本版本中提及與本公司關係的客戶/供應商/服務提供者各方的關係。此類商標的所有權利均由其各自所有者或被授權人保留。
Statement Regarding Third-Party Investor Relations Firms
第三方投資者關係公司之聲明
Disclosures relating to investor relations firms retained by TAAT Global Alternatives Inc. can be found under the Company's profile on .
有關 TAAT 保留的投資者關係公司的披露 全球替代品公司可以在該公司的個人資料下找到 。
譯文內容由第三人軟體翻譯。